The Position of Pranlukast, a Cysteinyl Leukotriene Receptor Antagonist, in the Long-Term Treatment of Asthma

Publisher： Karger

E-ISSN： 1423-0356|71|3|225-232

ISSN： 0025-7931

Source： Respiration, Vol.71, Iss.3, 2004-05, pp. : 225-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pranlukast, a Cysteinyl Leukotriene Type 1 Receptor Antagonist, Attenuates the Progression but Not the Onset of Silica-Induced Pulmonary Fibrosis in Mice

By  

International Archives of Allergy and Immunology, Vol. 158, Iss. 3, 2012-02 ,pp. : 241-251

Karger

Access to resources Recommend Favorite

Effect of the Cysteinyl Leukotriene Antagonist Pranlukast on Transendothelial Migration of Eosinophils

By  

International Archives of Allergy and Immunology, Vol. 137, Iss. 1, 2005-06 ,pp. : 2-6

Karger

Access to resources Recommend Favorite

Effects of a Cysteinyl Leukotriene Dual 1/2 Receptor Antagonist on Antigen-Induced Airway Hypersensitivity and Airway Inflammation in a Guinea Pig Asthma Model

By  

International Archives of Allergy and Immunology, Vol. 155, Iss. 1, 2011-06 ,pp. : 90-95

Karger

Access to resources Recommend Favorite

Pranlukast, a Leukotriene Receptor Antagonist, Inhibits Interleukin-5 Production via a Mechanism Distinct from Leukotriene Receptor Antagonism

By  

International Archives of Allergy and Immunology, Vol. 136, Iss. 2, 2005-02 ,pp. : 165-172

Karger

Access to resources Recommend Favorite

Changes in Plasma Serotonin Concentration and Acceleration Plethysmograms in Patients with Raynaud's Phenomenon after Long‐term Treatment with a 5‐HT2 Receptor Antagonist

By  

THE JOURNAL OF DERMATOLOGY, Vol. 27, Iss. 10, 2000-10 ,pp. : 643-650

John Wiley & Sons Inc

Access to resources Recommend Favorite